Tissue Regenix Group PLC Option Exercise and Total Voting Rights (8323Q)
June 23 2020 - 10:07AM
UK Regulatory
TIDMTRX
RNS Number : 8323Q
Tissue Regenix Group PLC
23 June 2020
Tissue Regenix Group Plc
("Tissue Regenix" or the "Company")
PDMR dealing and issue of equity
Leeds, 23 June 2020- Tissue Regenix Group plc (AIM:TRX), the
regenerative medical devices company, announces the exercise of
options by Shervanthi Homer-Vanniasinkam, a Non-Executive
Director.
In consequence of the exercise of options, the Company has
issued and allotted 1,388,222 ordinary shares of 0.1p each in the
Company (the "Option Shares") at an exercise price of 0.00456p
pence per share. The Option Shares will rank pari passu with the
existing ordinary shares. An application has been made for the
Option Shares to be admitted to trading on AIM which is expected to
take place at 8:00am on or around 29 June 2020.
Following the issue of the Option Shares, Ms Homer-Vanniasinkam
will be interested in a total of 1,638,222 shares in the Company
representing 0.02% of the enlarged issued share capital.
Total voting rights
Following the issue of the 1,388,222 new ordinary shares, the
Company will have a total of 7,032,985,756 ordinary shares of 0.1p
each in issue. The above figure may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc Tel: 0330 430
Caitlin Pearson, Head of Communications 3073
--------------------------------------------- ---------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710
Adviser and Broker) 7600
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- ---------------
FTI Consulting Tel: 0203 727
Simon Conway / Victoria Foster Mitchell 1000
/ Mary Whittow
============================================= ===============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMRs") and persons
closely associated ("PCA") with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Shervanthi Homer-Vanniasinkam
--------------------- -----------------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------- -----------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
----------------------------------------------------------------
a) Description Ordinary Shares of 0.1p
of the financial
instrument,
type of instrument
--------------------- -----------------------------------------
b) Identification GB00B5SGVL29
code
--------------------- -----------------------------------------
c) Nature of the Exercise of options over Ordinary Shares
transaction
--------------------- -----------------------------------------
d) Price(s) and Volume(s):
volume(s) 1,388,222 Ordinary Shares
Price: 0.00456 pence per Ordinary Share
--------------------- -----------------------------------------
d) Aggregated N/A
information
- Aggregated
volume
- Price
--------------------- -----------------------------------------
e) Date of the 23 June 2020
transactions
--------------------- -----------------------------------------
f) Place of the Outside of a trading venue
transaction
--------------------- -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFJMJTMTATBIM
(END) Dow Jones Newswires
June 23, 2020 10:07 ET (14:07 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024
